WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke. Asundexian is an oral inhibitor of Factor Eleven (FXIa) 1 that Bayer is developing as a potential treatment for […]